Skip to main navigation Logo MENU Media Company Overview Akcea Therapeutics is a development and commercialization company focused on helping patients living with serious and rare diseases. Our priority is to bring transformative medicines to patients by driving clinical program execution, understanding patient and physician needs, preparing the market, creating market access, and commercializing our products on a global basis. News Releases Nov 9, 2020 WAYLIVRA▼® (volanesorsen), the first and only therapy for familial chylomicronaemia syndrome, an ultra-rare and life-threatening condition, to be available on the NHS in Scotland LONDON, UK, 9 November 2020 – Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Scottish Medicines Consortium (SMC) has... Nov 6, 2020 Ionis and Akcea recognize FCS Awareness Day with global community efforts to celebrate unsung heroes BOSTON and CARLSBAD, Calif., November 6, 2020 – Ionis Pharmaceuticals (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, today recognize the 3rd annual Familial Chylomicronemia... Nov 3, 2020 Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx) Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen... View All Events Akcea Therapeutics Q2 2020 Earnings Call Tuesday, August 4, 2020 4:30pm - 5:30pm EDT View All Media Resources For media inquiries, please contact: info@akceatx.com or call (617) 207-0202. Image Downloads Akcea logo Akcea Logo Toolbar Footer Nav Careers | Privacy Policy | Terms of Use | Contact Akcea Therapeutics 22 Boston Wharf Road, 9th Floor Boston, MA 02210 (617) 207-0202 info@akceatx.com © 2020, all rights reserved

Skip to main navigation Logo MENU Press Releases Investor Alerts Year All Years 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 Keywords Go Advanced Search Nov 9, 2020 WAYLIVRA▼® (volanesorsen), the first and only therapy for familial chylomicronaemia syndrome, an ultra-rare and life-threatening condition, to be available on the NHS in Scotland Nov 6, 2020 Ionis and Akcea recognize FCS Awareness Day with global community efforts to celebrate unsung heroes Nov 3, 2020 Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx) Oct 30, 2020 Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product Oct 12, 2020 Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Show 5 per page Prev123456789…36Next Toolbar Footer Nav Careers | Privacy Policy | Terms of Use | Contact Akcea Therapeutics 22 Boston Wharf Road, 9th Floor Boston, MA 02210 (617) 207-0202 info@akceatx.com © 2020, all rights reserved